RecruitingNCT06452732

Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML

Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in Pediatric Acute Myeloid Leukaemia: a Prospective Study


Sponsor

Peking University People's Hospital

Enrollment

283 participants

Start Date

Nov 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Leukaemia is a major disease that seriously endangers human health, the long-term survival rate of acute myeloid leukaemia receiving conventional chemotherapy is only 10% to 45%, haematological relapse is the main cause of treatment failure in acute myeloid leukaemia, reducing the relapse rate is the key to improving the efficacy of acute leukaemia, biomarker-guided preemptive therapy is an effective way to reduce the recurrence of leukaemia, existing markers to predict the recurrence has a high false Existing markers have high false-negative and false-positive rates for predicting relapse, and improving the accuracy of leukaemia relapse prediction is a major clinical problem that needs to be solved urgently. The group has found that circulating leukaemia stem cells remaining after chemotherapy are the key to relapse, therefore, we propose to conduct a multicentre prospective clinical study on the prediction of acute leukaemia relapse by circulating leukaemia stem cells.


Eligibility

Max Age: 18 Years

Inclusion Criteria3

  • Newly diagnoses candidates with acute myeloid leukemia.
  • Lower than or equal to 18 years-old;
  • Subjects are able to provide written informed consent.

Exclusion Criteria4

  • Subjects who cannot comply with the study;
  • Subjects with severe cardiac disease (ejection fraction\<50% ), liver disease (total bilirubin \>34umol/L, ALT and AST\>1.5×upper limit normal) or kidney disease (Serum creatinine\>130umol/L).
  • Subjects with severe infection.
  • Subjects with other conditions that cannot receive chemotherapy or transplantation.

Interventions

OTHERMFC for the determination of leukemia stem cell

MFC for the determination of leukemia stem cell


Locations(2)

Peking University People's Hospital

Beijing, Beijing Municipality, China

People's Hospital of Peking University

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06452732


Related Trials